Thursday, June 11

Browsing: RelacorilantNabPaclitaxel

Support

Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer

By NewsCancerApril 11, 20260

Treatment with relacorilant (Lifyorli) plus nab-paclitaxel (Abraxane) led to a 35% reduction in the risk of death compared with nab-paclitaxel…

Treatments

Relacorilant/Nab-Paclitaxel Offers New Option in Platinum-Resistant Ovarian Cancer

By NewsCancerApril 3, 20260

Relacorilant (Lifyorli) plus nab-paclitaxel (Abraxane) was approved by the FDA as a treatment for patients with platinum-resistant epithelial ovarian, fallopian…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

Browsing: RelacorilantNabPaclitaxel

Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer

Relacorilant/Nab-Paclitaxel Offers New Option in Platinum-Resistant Ovarian Cancer

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

Latest Post

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

Subscribe to Updates

What's Hot

Browsing: RelacorilantNabPaclitaxel